HOWL

Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Wall Street analysts forecast HOWL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOWL is 9.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Werewolf Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Werewolf Therapeutics Inc. EPS for the last quarter amounts to -0.36 USD, decreased -5.26 % YoY.

Werewolf Therapeutics Inc (HOWL) has 46 emplpoyees as of January 08 2026.

Today HOWL has the market capitalization of 30.59M USD.